Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update.
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Abnormalities of Motor Imagery and Relationship With Depressive Symptoms in Mildly Disabling Relapsing-Remitting Multiple Sclerosis.
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis.
Management of children with multiple sclerosis.
Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.
Teva and Takeda announce agreement for glatiramer acetate for multiple sclerosis treatment in Japan
CHMP recommends granting a marketing authorization for Santhera's Raxone® for the treatment of Leber's Hereditary Optic Neuropathy (LHON)
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.
Low-contrast visual tests reveal better alemtuzumab efficacy
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects.
Topical Application of Fingolimod Perturbs Cutaneous Inflammation.
Treating multiple sclerosis with monoclonal antibodies: a 2013 update.
1,25-Dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis.
Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab.
Identification of protein networks involved in the disease course of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 mg GA Depot in Subjects With RRMS
Receptos begins enrollment of Phase 3 trial of RPC1063 in relapsing multiple sclerosis
Apitope Announces Completion of Enrolment in Phase IIA Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
Current and future drugs for treatment of MS-associated bladder dysfunction.
Cognitive impairment as unusual first manifestation in late-onset relapsing-remitting multiple sclerosis.
Translating Fatigue to Human Performance.
Slowing of brain atrophy and reductions in new multiple sclerosis lesions sustained at three years in patients treated with Genzyme's LemtradaTM
A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis.
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.

Pages